How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,178 results for

Mycobacterium Avium Complex

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. PCR-Based Rapid Identification System Using Bridged Nucleic Acids for Detection of Clarithromycin-Resistant Mycobacterium avium-M. intracellulare Complex Isolates Full Text available with Trip Pro

PCR-Based Rapid Identification System Using Bridged Nucleic Acids for Detection of Clarithromycin-Resistant Mycobacterium avium-M. intracellulare Complex Isolates The nontuberculous mycobacteria (NTM) cause miscellaneous disorders in humans, especially in the lungs, which present with a variety of radiological features. To date, knowledge of the pathogenic role of the Mycobacterium avium-intracellulare complex (MAC) in the human lung and the definitive criteria for initiating multidrug therapy

2016 Journal of clinical microbiology

102. Clofazimine in the Treatment of Pulmonary Mycobacterium Avium Complex (MAC)

Clofazimine in the Treatment of Pulmonary Mycobacterium Avium Complex (MAC) Clofazimine in the Treatment of Pulmonary Mycobacterium Avium Complex (MAC) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Clofazimine in the Treatment of Pulmonary Mycobacterium Avium Complex (MAC) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT02968212 Recruitment Status : Recruiting First Posted : November 18, 2016 Last Update Posted : February

2016 Clinical Trials

103. In Vitro Susceptibility Testing of Bedaquiline Against Mycobacterium avium Complex. Full Text available with Trip Pro

In Vitro Susceptibility Testing of Bedaquiline Against Mycobacterium avium Complex. We performed bedaquiline broth microdilution susceptibility testing using Clinical and Laboratory Standards Institute (CLSI) guidelines on 103 respiratory isolates of Mycobacterium avium complex (MAC), including multidrug-resistant isolates. Approximately 90% of isolates had bedaquiline MICs of ≤0.008 μg/ml, and 102/103 isolates had MICs of ≤0.015 μg/ml. Bedaquiline has excellent potential for use in patients

2016 Antimicrobial Agents and Chemotherapy

104. Relapse Versus Reinfection of Mycobacterium avium complex Pulmonary Disease: Patient Characteristics and Macrolide Susceptibility. (Abstract)

Relapse Versus Reinfection of Mycobacterium avium complex Pulmonary Disease: Patient Characteristics and Macrolide Susceptibility. Clinical recurrence of Mycobacterium avium complex (MAC) pulmonary disease occurs in 10 to 40% of patients treated for this disease process. Episodes of clinical recurrence may represent true relapse from the same MAC strain or reinfection with a new strain.The purpose of this study was to investigate the clinical implications of separating patients into these two

2016 Annals of the American Thoracic Society

105. Clinical Characteristics, Treatment Outcomes, and Resistance Mutations Associated with Macrolide-Resistant Mycobacterium avium Complex Lung Disease. Full Text available with Trip Pro

Clinical Characteristics, Treatment Outcomes, and Resistance Mutations Associated with Macrolide-Resistant Mycobacterium avium Complex Lung Disease. Macrolide antibiotics are key components of the multidrug treatment regimen for treating lung disease (LD) due to Mycobacterium avium complex (MAC). Despite the emergence of macrolide resistance, limited data are available on macrolide-resistant MAC-LD. This study evaluated the clinical features and treatment outcomes of patients with macrolide

2016 Antimicrobial Agents and Chemotherapy

106. Immune Reconstitution Inflammatory Syndrome Presenting as Mycobacterium Avium Complex Lymphadenitis Full Text available with Trip Pro

Immune Reconstitution Inflammatory Syndrome Presenting as Mycobacterium Avium Complex Lymphadenitis 28000104 2019 03 08 1525-1497 32 6 2017 06 Journal of general internal medicine J Gen Intern Med Immune Reconstitution Inflammatory Syndrome Presenting as Mycobacterium Avium Complex Lymphadenitis. 712-713 10.1007/s11606-016-3956-z Matusz-Fisher Ashley A Department of Internal Medicine, Carolinas HealthCare System, Charlotte, NC, USA. Ashley.Matuszfisher@carolinashealthcare.org. Bodie Wesley W (...) Department of Internal Medicine, Carolinas HealthCare System, Charlotte, NC, USA. Montgomery Thomas T Department of Internal Medicine, Carolinas HealthCare System, Charlotte, NC, USA. eng Journal Article 2016 12 20 United States J Gen Intern Med 8605834 0884-8734 Mycobacterium avium complex human immunodeficiency virus immune reconstitution inflammatory syndrome 2016 09 28 2016 12 05 2016 11 04 2016 12 22 6 0 2016 12 22 6 0 2016 12 22 6 0 ppublish 28000104 10.1007/s11606-016-3956-z 10.1007/s11606-016

2016 Journal of General Internal Medicine

107. Preliminary Evaluation of a Sitafloxacin-Containing Regimen for Relapsed or Refractory Pulmonary Mycobacterium avium Complex Disease Full Text available with Trip Pro

Preliminary Evaluation of a Sitafloxacin-Containing Regimen for Relapsed or Refractory Pulmonary Mycobacterium avium Complex Disease Although sitafloxacin (STFX) is known to have a favorable minimum inhibitory concentration for Mycobacterium avium, few studies have evaluated the clinical efficacy of an STFX-containing regimen for pulmonary M avium complex (MAC) disease. To evaluate the clinical efficacy of STFX-containing regimens for relapsed or refractory pulmonary MAC disease, we

2016 Open forum infectious diseases

108. Thioridazine as Chemotherapy For Mycobacterium avium Complex Diseases. Full Text available with Trip Pro

Thioridazine as Chemotherapy For Mycobacterium avium Complex Diseases. Mycobacterium avium-intracellulare complex (MAC) causes an intractable intracellular infection that presents as chronic pulmonary disease. Currently, therapy consists of ethambutol and macrolides and takes several years to complete. The neuroleptic phenothiazine thioridazine kills mycobacteria by inhibiting the electron transport chain. In several experiments with bacterial populations of up to 10(12) CFU/ml, we failed

2016 Antimicrobial Agents and Chemotherapy

109. Program Cell Death Receptor 1 in Mycobacterium Avium Complex Lung Disease

Program Cell Death Receptor 1 in Mycobacterium Avium Complex Lung Disease Program Cell Death Receptor 1 in Mycobacterium Avium Complex Lung Disease - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Program (...) Cell Death Receptor 1 in Mycobacterium Avium Complex Lung Disease The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02779049 Recruitment Status : Completed First Posted : May 20, 2016 Last Update Posted : December 15, 2016 Sponsor: National Taiwan University Hospital Information provided

2016 Clinical Trials

110. High recurrence rate supports need for secondary prophylaxis in non-HIV patients with disseminated mycobacterium avium complex infection: a multi-center observational study. Full Text available with Trip Pro

High recurrence rate supports need for secondary prophylaxis in non-HIV patients with disseminated mycobacterium avium complex infection: a multi-center observational study. Long-term outcomes in non-HIV immunocompromised patients with disseminated Mycobacterium avium complex (dMAC) infections are unknown and the need for post-treatment secondary prophylaxis against MAC is uncertain in this setting. The objective of this study was to determine the need of continuing secondary anti-MAC

2016 BMC Infectious Diseases

111. Macrolide-Resistant Mycobacterium avium Complex Lung Infection: An Analysis of 102 Consecutive Cases. (Abstract)

Macrolide-Resistant Mycobacterium avium Complex Lung Infection: An Analysis of 102 Consecutive Cases. The management of macrolide-resistant Mycobacterium avium complex (MR-MAC) pulmonary disease is difficult and is thought to be analogous to that of multidrug-resistant tuberculosis (MDR-TB).This study aimed to clarify the cause of MR-MAC, to see how its management affected outcome, and to compare its prognosis with that of MDR-TB.The medical records of 102 consecutive cases with MR-MAC

2016 Annals of the American Thoracic Society

112. Peak Plasma Concentration of Azithromycin and Treatment Responses in Mycobacterium avium Complex Lung Disease. Full Text available with Trip Pro

Peak Plasma Concentration of Azithromycin and Treatment Responses in Mycobacterium avium Complex Lung Disease. Macrolides, such as azithromycin (AZM) and clarithromycin, are the cornerstones of treatment for Mycobacterium avium complex lung disease (MAC-LD). Current guidelines recommend daily therapy with AZM for cavitary MAC-LD and intermittent therapy for noncavitary MAC-LD, but the effectiveness of these regimens has not been thoroughly investigated. This study evaluated associations between (...) microbiological response and estimated peak plasma concentrations (Cmax) of AZM. The AZM Cmax was measured in patients receiving daily therapy (250 mg of AZM daily, n = 77) or intermittent therapy (500 mg of AZM three times weekly, n = 89) for MAC-LD and daily therapy for Mycobacterium abscessus complex LD (MABC-LD) (250 mg of AZM daily, n = 55). The AZM Cmax was lower with the daily regimen for MAC-LD (median, 0.24 μg/ml) than with the intermittent regimen for MAC-LD (median, 0.65 μg/ml; P < 0.001) or daily

2016 Antimicrobial Agents and Chemotherapy

113. Analysis of drug treatment outcome in clarithromycin-resistant Mycobacterium avium complex lung disease. Full Text available with Trip Pro

Analysis of drug treatment outcome in clarithromycin-resistant Mycobacterium avium complex lung disease. Although the isolation of clarithromycin (CAM)-resistant Mycobacterium avium complex (MAC) indicates a poor treatment outcome and increased mortality, there have been only a few reports on drug treatment for CAM-resistant MAC lung disease. We aimed to reveal the effectiveness of the continuation of a macrolide and the use of a multidrug regimen in the treatment of CAM-resistant MAC lung

2016 BMC Infectious Diseases

114. Characteristics of pulmonary Mycobacterium avium complex disease diagnosed later in follow-up after negative mycobacterial study including bronchoscopy. Full Text available with Trip Pro

Characteristics of pulmonary Mycobacterium avium complex disease diagnosed later in follow-up after negative mycobacterial study including bronchoscopy. We occasionally experience cases suspected of pulmonary Mycobacterium avium complex (MAC) disease without positive bacterial cultures.To evaluate features of pulmonary MAC cases diagnosed later in the follow-up after negative intensive investigation.We defined and compared three groups; the first study negative (FSN) group, the first study

2015 Respiratory medicine

115. Clinical efficacy of anti-glycopeptidolipid-core IgA test for diagnosing Mycobacterium avium complex infection in lung. (Abstract)

Clinical efficacy of anti-glycopeptidolipid-core IgA test for diagnosing Mycobacterium avium complex infection in lung. It is difficult to verify the bacteriological diagnosis of Mycobacterium avium complex (MAC) infection. The anti-glycopeptidolipid (GPL)-core IgA antibody test was recently developed as a diagnostic method for MAC pulmonary disease. Only a few studies evaluate its clinical efficacy. We conducted retrospective evaluations of clinical characteristics of patients suspected of MAC

2015 Respirology

116. Assessing primary and secondary resistance to clarithromycin and amikacin in infections due to Mycobacterium avium complex. Full Text available with Trip Pro

Assessing primary and secondary resistance to clarithromycin and amikacin in infections due to Mycobacterium avium complex. 26324275 2016 08 04 2018 11 13 1098-6596 59 11 2015 Nov Antimicrobial agents and chemotherapy Antimicrob. Agents Chemother. Assessing primary and secondary resistance to clarithromycin and amikacin in infections due to Mycobacterium avium complex. 7153-5 10.1128/AAC.01027-15 Renvoisé Aurélie A Centre National de Référence des Mycobactéries et de la Résistance des (...) Clarithromycin IM Amikacin pharmacology Anti-Bacterial Agents pharmacology Clarithromycin pharmacology Drug Resistance, Bacterial genetics Microbial Sensitivity Tests Mycobacterium avium Complex drug effects genetics 2015 9 2 6 0 2015 9 2 6 0 2016 8 5 6 0 ppublish 26324275 AAC.01027-15 10.1128/AAC.01027-15 PMC4604394 Tuber Lung Dis. 2000;80(1):1-4 10897378 Curr Drug Targets Infect Disord. 2002 Dec;2(4):355-70 12570741 J Antimicrob Chemother. 1995 Jul;36(1):129-36 8537260 Am J Respir Crit Care Med. 2007 Feb

2015 Antimicrobial Agents and Chemotherapy

117. Serum concentrations of clarithromycin and rifampicin in pulmonary Mycobacterium avium complex disease: long-term changes due to drug interactions and their association with clinical outcomes Full Text available with Trip Pro

Serum concentrations of clarithromycin and rifampicin in pulmonary Mycobacterium avium complex disease: long-term changes due to drug interactions and their association with clinical outcomes Concomitant use of clarithromycin (CAM) and rifampicin (RFP) for the treatment of pulmonary Mycobacterium avium complex (MAC) disease affects the systemic concentrations of both drugs due to CYP3A4-related interactions. To date, however, there has been no report that investigates the long-term relationship

2015 Journal of pharmaceutical health care and sciences

118. Long Term Follow Up Of Mycobacterium Avium Complex Lung Disease In Patients Treated With Regimens Including Clofazimine and/or Rifampin. (Abstract)

Long Term Follow Up Of Mycobacterium Avium Complex Lung Disease In Patients Treated With Regimens Including Clofazimine and/or Rifampin. Mycobacterium avium complex (MAC) lung disease requires prolonged treatment with multiple antibiotics. Drug intolerances and interactions are common with the current recommended treatment. There is limited information on outcomes with alternative medications.Retrospective review including adult patients with MAC lung disease who were treated and monitored

2015 Chest

119. Successful resumption of tocilizumab for rheumatoid arthritis after resection of a pulmonary Mycobacterium avium complex lesion: a case report. Full Text available with Trip Pro

Successful resumption of tocilizumab for rheumatoid arthritis after resection of a pulmonary Mycobacterium avium complex lesion: a case report. Biological agents inhibiting TNF-α and other molecules involved in inflammatory cascade have been increasingly used to treat rheumatoid arthritis (RA). However, it remains controversial whether biological agents can be used safely in a patient with an underlying chronic infectious disease.A 63-year-old woman who had been treated with tocilizumab (TCZ (...) ), anti-interleukin-6 receptor antibody, for RA presented to our outpatient clinic due to hemoptysis. She was diagnosed with pulmonary Mycobacterium avium complex (MAC) infection, and high-resolution computed tomography (HRCT) showed a single cavitary lesion in the right upper lobe. After diagnosis of pulmonary MAC disease, TCZ was discontinued and combination chemotherapy with clarithromycin, rifampicin, ethambutol and amikacin was started for MAC pulmonary disease. Since the lesion was limited

2015 BMC pulmonary medicine

120. Middle-aged to elderly women have a higher asymptomatic infection rate with Mycobacterium avium complex, regardless of body habitus. Full Text available with Trip Pro

Middle-aged to elderly women have a higher asymptomatic infection rate with Mycobacterium avium complex, regardless of body habitus. Mycobacterium avium complex (MAC) pulmonary disease is prevalent in middle-aged to elderly women with a thin body habitus. By comparing the rate of serologically diagnosed asymptomatic MAC infection and body mass index among 1033 healthy subjects, we find that middle-aged to elderly women became infected with MAC, regardless of their body habitus. © 2015 Asian

2015 Respirology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>